336 related articles for article (PubMed ID: 31226367)
1. Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors.
He H; Liu C; Liu Y; Liu X; Wu Y; Fan J; Zhao L; Cao Y
Eur J Pharm Biopharm; 2019 Sep; 142():153-164. PubMed ID: 31226367
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
3. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
Qin M; Xia H; Xu W; Chen B; Wang Y
Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
5. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
6. High-resolution 3D visualization of nanomedicine distribution in tumors.
Moss JI; Barjat H; Emmas SA; Strittmatter N; Maynard J; Goodwin RJA; Storm G; Lammers T; Puri S; Ashford MB; Barry ST
Theranostics; 2020; 10(2):880-897. PubMed ID: 31903157
[TBL] [Abstract][Full Text] [Related]
7. Transcytosis-enabled active extravasation of tumor nanomedicine.
Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
[TBL] [Abstract][Full Text] [Related]
8. Design considerations for nanotherapeutics in oncology.
Stylianopoulos T; Jain RK
Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
[TBL] [Abstract][Full Text] [Related]
9. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
10. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
11. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
Burton JK; Bottino D; Secomb TW
AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
Islam R; Maeda H; Fang J
Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
[TBL] [Abstract][Full Text] [Related]
13. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting via EPR: Strategies to enhance patient responses.
Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
[TBL] [Abstract][Full Text] [Related]
15. Modulating tumor mechanics with nanomedicine for cancer therapy.
Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
[TBL] [Abstract][Full Text] [Related]
16. Enhanced permeability and retention effect-focused tumor-targeted nanomedicines: latest trends, obstacles and future perspective.
Shekhar S; Chauhan M; Sonali ; Yadav B; Dutt R; Hu L; Muthu MS; Singh RP
Nanomedicine (Lond); 2022 Aug; 17(18):1213-1216. PubMed ID: 36136592
[No Abstract] [Full Text] [Related]
17. Using imaging modalities to predict nanoparticle distribution and treatment efficacy in solid tumors: The growing role of ultrasound.
Cooley MB; Wegierak D; Exner AA
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1957. PubMed ID: 38558290
[TBL] [Abstract][Full Text] [Related]
18. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based combination nanomedicines for cancer therapy.
Li Y; Lin W
Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
[TBL] [Abstract][Full Text] [Related]
20. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.
Miao L; Lin CM; Huang L
J Control Release; 2015 Dec; 219():192-204. PubMed ID: 26277065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
